Barclays Issues Positive Forecast for Intuitive Surgical (NASDAQ:ISRG) Stock Price

Intuitive Surgical (NASDAQ:ISRG) had its target price boosted by Barclays from $610.00 to $674.00 in a research note published on Monday morning.

ISRG has been the subject of a number of other research reports. JPMorgan Chase & Co. boosted their target price on shares of Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research report on Friday. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $522.00 to $650.00 in a research note on Monday, December 2nd. Piper Sandler reissued an “overweight” rating and issued a $670.00 target price (up from $538.00) on shares of Intuitive Surgical in a report on Friday. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Finally, Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Trading Down 1.8 %

ISRG opened at $573.48 on Monday. The stock has a market cap of $204.26 billion, a price-to-earnings ratio of 92.20, a PEG ratio of 5.19 and a beta of 1.39. The stock has a fifty day moving average price of $547.16 and a 200 day moving average price of $505.21. Intuitive Surgical has a 1 year low of $364.17 and a 1 year high of $616.00.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 270 shares of Intuitive Surgical stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total value of $145,840.50. Following the completion of the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at approximately $4,730,093.55. This trade represents a 2.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Gary S. Guthart sold 18,151 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. This represents a 42.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,265 shares of company stock worth $21,964,281. Company insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ISRG. Berbice Capital Management LLC bought a new position in Intuitive Surgical in the 4th quarter worth about $26,000. Godsey & Gibb Inc. boosted its position in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. purchased a new stake in shares of Intuitive Surgical during the third quarter worth about $33,000. Decker Retirement Planning Inc. purchased a new stake in Intuitive Surgical during the 4th quarter worth approximately $36,000. Finally, Capital Performance Advisors LLP acquired a new position in shares of Intuitive Surgical in the 3rd quarter valued at $38,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.